HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas Brechenmacher Selected Research

Hormones (Hormone)

2/2014Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas Brechenmacher Research Topics

Disease

3Tuberous Sclerosis (Bourneville's Disease)
05/2016 - 06/2014
2Angiomyolipoma
05/2016 - 06/2014
2Astrocytoma (Pilocytic Astrocytoma)
01/2016 - 06/2014
1Primitive Neuroectodermal Tumors (PNET)
10/2016
1Hypercholesterolemia
10/2016
1Hyperglycemia
10/2016
1Neuroendocrine Tumors (Neuroendocrine Tumor)
10/2016
1Disease Progression
10/2016
1Renal Cell Carcinoma (Grawitz Tumor)
10/2016
1Lymphangioleiomyomatosis (Lymphangiomyomatosis)
05/2016
1Virus Diseases (Viral Diseases)
01/2016
1Bacteremia
01/2016
1Breast Neoplasms (Breast Cancer)
02/2014

Drug/Important Bio-Agent (IBA)

6EverolimusFDA Link
10/2016 - 02/2014
3trans-sodium crocetinate (crocetin)IBA
05/2016 - 06/2014
1TOR Serine-Threonine KinasesIBA
10/2016
1Biomarkers (Surrogate Marker)IBA
05/2016
1Vascular Endothelial Growth Factor DIBA
05/2016
1Alkaline PhosphataseIBA
01/2016
1Epidermal Growth Factor (EGF)IBA
02/2014
1Hormones (Hormone)IBA
02/2014
1exemestane (Aromasin)FDA Link
02/2014
1Aromatase InhibitorsIBA
02/2014

Therapy/Procedure

1Duration of Therapy
10/2016
1Therapeutics
02/2014